PetMed Express Reports 22.7% Decline in Net Sales and $34.2 Million Net Loss for Quarter Ended June 30, 2025

PetMed Express, Inc. reported a significant decline in financial performance for the quarter ended June 30, 2025, with net sales dropping to $51.2 million, a decrease of 22.7% from $66.2 million in the same period last year. The company attributed this decline primarily to reduced advertising effectiveness, increased consumer promotional usage, and a drop in prescription medication sales. Gross profit also fell by 24.3% to approximately $14.4 million, reflecting a gross margin of 28.1%, down from 28.8% a year earlier. The company recorded a net loss of $34.2 million, compared to a net income of $3.8 million in the prior year, resulting in a loss per share of $1.65.

The financial results were impacted by a substantial increase in operating expenses, which surged to $48.5 million from $14.7 million in the previous year. This increase was largely driven by a $27.3 million impairment charge related to goodwill and intangible assets, alongside a rise in general and administrative expenses, which increased by 165.7% to $12.9 million. The company also reported a significant rise in stock-based compensation expenses, which contributed to the overall increase in operating costs.

In terms of operational metrics, PetMed Express acquired approximately 85,000 new customers during the quarter, a decrease from 120,000 in the same period last year. Reorder sales accounted for 80.7% of total sales, while new order sales represented 16.1%. The company’s membership fees also declined by 29.9%, indicating challenges in customer retention and engagement. The total number of shares outstanding as of June 30, 2025, was 21,369,521.

Looking ahead, PetMed Express faces ongoing challenges due to macroeconomic factors such as inflation and rising interest rates, which may impact consumer spending and demand for its products. The company has indicated that it will continue to monitor its operational strategies and cost structures to adapt to these market conditions. Additionally, the recent resignation of key executives, including the CEO and CFO, has led to interim appointments, which may affect the company's strategic direction in the near term. The board has also suspended the quarterly dividend to focus on growth initiatives, reflecting a shift in capital allocation priorities.